The global malignant pleural effusion market is expected to garner a market value of USD 4.5 Billion in 2023 and is expected to accumulate a market value of USD 8.06 Billion by registering a CAGR of 6% in the forecast period 2023-2033. The increasing incidence of pleural effusion disease and rising awareness of advancement in pleural effusions treatment with different types of techniques in the current market works as a driver for the market. The market for Malignant Pleural Effusion registered a CAGR of 4% in the historical period 2017-2022.
Growth of the Malignant Pleural Effusion market can be attributed to the rising burden of various diseases such as cancer and heart failure. The increasing burden of diseases in the United States is expected to create opportunities for the pleural effusions market. The data updated by the American Cancer Society’s Cancer Statistics 2022, nearly 1.9 million new cancer cases are estimated to be diagnosed in the United States in the year 2022.
In addition to this, the rising prevalence of pleural effusions has been contributing to the market growth. An article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people. Therefore, various factors such as awareness in wellness and health along with the research and development activities in the field like emerging novel therapeutics are increasing the efficacy of medicine as well as treatment.
Key Takeaways from the Market Study
- From 2017-2022, the Malignant Pleural Effusion market grew at CAGR of 4%.
- The global Malignant Pleural Effusion market is expected to grow with a 6% CAGR during 2023-2033.
- As of 2033, the Malignant Pleural Effusion market is expected to reach US$ 8.06 Billion
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 45% market share for the Malignant Pleural Effusion market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
“Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in the developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.” says an FMI analyst
Market Competition
Key players in the Malignant Pleural Effusion market are B. Braun SE, Becton, Dickinson and Company, Bicakcilar, Biometrix, Cook Medical, Grena, Redax, Rocket Medical, and Smith Medical.
- In September 2021, BDR Pharma launched BIAPENEM to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections. Biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid).
- In April 2022, the study titled “IFN-γ Combined with T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites” was registered in ClinicalTrials.gov for Malignant Pleural Effusion.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Malignant Pleural Effusion market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of treatment (Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage and Pleurodesis, Indwelling Pleural Catheter), End-users (Hospitals, Ambulatory Clinics, Others), diagnosis (Imaging Tests, Pleural Thoracentesis, Pleural Fluid Cytology,Immunohistochemical Tests, Pleural Biopsy, Thoracoscopy/Pleuroscopy) & region.
Key Segments Profiled in the Malignant Pleural Effusion Industry Survey
By Diagnosis:
- Imaging Tests
- Pleural Thoracentesis
- Pleural Fluid Cytology
- Immunohistochemical Tests
- Pleural Biopsy
- Thoracoscopy/Pleuroscopy
By End User:
- Hospitals
- Ambulatory Clinics
- Others
By Treatment:
- Systemic Therapy
- Therapeutic Thoracentesis
- Thoracic Drainage and Pleurodesis
- Indwelling Pleural Catheter
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube